IL155874A0 - Treatment of anxiety disorders - Google Patents
Treatment of anxiety disordersInfo
- Publication number
- IL155874A0 IL155874A0 IL15587401A IL15587401A IL155874A0 IL 155874 A0 IL155874 A0 IL 155874A0 IL 15587401 A IL15587401 A IL 15587401A IL 15587401 A IL15587401 A IL 15587401A IL 155874 A0 IL155874 A0 IL 155874A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- anxiety disorders
- anxiety
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24901000P | 2000-11-15 | 2000-11-15 | |
| US26536201P | 2001-01-31 | 2001-01-31 | |
| PCT/US2001/027801 WO2002040006A2 (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL155874A0 true IL155874A0 (en) | 2003-12-23 |
Family
ID=26939750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15587401A IL155874A0 (en) | 2000-11-15 | 2001-11-06 | Treatment of anxiety disorders |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1395253A2 (en) |
| JP (1) | JP2004529073A (en) |
| KR (1) | KR20030051812A (en) |
| CN (1) | CN1822825A (en) |
| AU (1) | AU2002217757A1 (en) |
| BR (1) | BR0115301A (en) |
| CA (1) | CA2426069A1 (en) |
| CZ (1) | CZ20031339A3 (en) |
| EA (1) | EA200300567A1 (en) |
| HR (1) | HRP20030384A2 (en) |
| IL (1) | IL155874A0 (en) |
| MX (1) | MXPA03004190A (en) |
| NO (1) | NO20032156D0 (en) |
| PL (1) | PL366119A1 (en) |
| SK (1) | SK5422003A3 (en) |
| WO (1) | WO2002040006A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL363840A1 (en) * | 2001-03-06 | 2004-11-29 | Eli Lilly And Company | Inhibitor of monoamine uptake |
| EP1530476A1 (en) * | 2002-08-14 | 2005-05-18 | Pharmacia & Upjohn Company LLC | Use of reboxetine for the treatment of hot flashes |
| GB0309440D0 (en) * | 2003-04-25 | 2003-06-04 | Lilly Co Eli | Quinolone derivatives |
| WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
| DE602004014823D1 (en) * | 2003-12-12 | 2008-08-14 | Lilly Co Eli | SELECTIVE NOREPINEPHRINE RECOVERY INHIBITOR FOR THE TREATMENT OF HITZEWALLUNGEN |
| EP2234960A2 (en) | 2008-01-09 | 2010-10-06 | Mayo Foundation for Medical Education and Research | Inhibiting neurotransmitter reuptake |
| WO2011056788A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| WO2011056773A2 (en) * | 2009-11-03 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| WO2014159251A2 (en) | 2013-03-14 | 2014-10-02 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| EA202192084A1 (en) * | 2019-02-01 | 2021-10-20 | ХОФФМАН ТЕКНОЛОДЖИЗ ЭлЭлСи. | COMPOSITIONS AND METHODS FOR TREATMENT OF ANXIETY DISORDERS |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2931997A (en) * | 1996-05-07 | 1997-11-26 | Merck & Co., Inc. | Treatment of mood disorders with a growth hormone secretagogue |
| IT1305322B1 (en) * | 1998-04-23 | 2001-05-04 | Pharmacia & Upjohn Spa | Use of reboxetine for treating obsessive compulsive disorder and panic disorder |
| SK286669B6 (en) * | 1999-07-01 | 2009-03-05 | Pharmacia & Upjohn Company | Use of optically pure (S,S)-reboxetine or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of peripheral neuropathy |
-
2001
- 2001-11-06 WO PCT/US2001/027801 patent/WO2002040006A2/en not_active Application Discontinuation
- 2001-11-06 EP EP01996376A patent/EP1395253A2/en not_active Withdrawn
- 2001-11-06 AU AU2002217757A patent/AU2002217757A1/en not_active Abandoned
- 2001-11-06 PL PL01366119A patent/PL366119A1/en not_active Application Discontinuation
- 2001-11-06 BR BR0115301-3A patent/BR0115301A/en not_active IP Right Cessation
- 2001-11-06 CN CNA01818927XA patent/CN1822825A/en active Pending
- 2001-11-06 MX MXPA03004190A patent/MXPA03004190A/en unknown
- 2001-11-06 EA EA200300567A patent/EA200300567A1/en unknown
- 2001-11-06 CZ CZ20031339A patent/CZ20031339A3/en unknown
- 2001-11-06 CA CA002426069A patent/CA2426069A1/en not_active Abandoned
- 2001-11-06 IL IL15587401A patent/IL155874A0/en unknown
- 2001-11-06 JP JP2002542380A patent/JP2004529073A/en active Pending
- 2001-11-06 SK SK542-2003A patent/SK5422003A3/en not_active Application Discontinuation
- 2001-11-06 KR KR10-2003-7006523A patent/KR20030051812A/en not_active Application Discontinuation
-
2003
- 2003-05-13 NO NO20032156A patent/NO20032156D0/en not_active Application Discontinuation
- 2003-05-14 HR HR20030384A patent/HRP20030384A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1822825A (en) | 2006-08-23 |
| WO2002040006A3 (en) | 2003-12-24 |
| NO20032156L (en) | 2003-05-13 |
| PL366119A1 (en) | 2005-01-24 |
| SK5422003A3 (en) | 2003-12-02 |
| AU2002217757A1 (en) | 2002-05-27 |
| EA200300567A1 (en) | 2004-10-28 |
| NO20032156D0 (en) | 2003-05-13 |
| MXPA03004190A (en) | 2003-09-22 |
| WO2002040006A2 (en) | 2002-05-23 |
| HRP20030384A2 (en) | 2003-08-31 |
| CA2426069A1 (en) | 2002-05-23 |
| BR0115301A (en) | 2004-12-14 |
| KR20030051812A (en) | 2003-06-25 |
| CZ20031339A3 (en) | 2003-10-15 |
| JP2004529073A (en) | 2004-09-24 |
| EP1395253A2 (en) | 2004-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0007193D0 (en) | Treatment of movrmrnt disorders | |
| AU8187701A (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
| IL155433A0 (en) | Treatment of t cell disorders | |
| AU2002360555A8 (en) | Treatment of genitourinary tract disorders | |
| IL155874A0 (en) | Treatment of anxiety disorders | |
| IL150479A0 (en) | Treatment of psoriasis | |
| IL150290A0 (en) | The use of mirtazapine for the treatment of sleep disorders | |
| IL140540A0 (en) | Treatment of anxiety disorders | |
| SI1468686T1 (en) | S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders | |
| IL151493A0 (en) | Use of dermaciclane for the treatment of anxiety and depression | |
| EP1303281A4 (en) | Methods of treatment | |
| GB0017951D0 (en) | Treatment of movement disorders | |
| GB0010496D0 (en) | Treatment of conditions of the central nervous system | |
| IL153788A0 (en) | Treatment of eating disorders using carboxyalkylethers | |
| GB0003228D0 (en) | Treatment of GI disorders | |
| GB0029955D0 (en) | Treatment of neuropsychiatric disorders | |
| GB0125371D0 (en) | Treatment of movement disorders | |
| GB0021060D0 (en) | Treatment of functional gastrointestinal disorders | |
| GB9924942D0 (en) | Treatment of movement disorders | |
| GB0014904D0 (en) | Methods of treatment | |
| GB0013928D0 (en) | Methods of treatment | |
| GB0004998D0 (en) | The treatment of functional gastrointestinal disorders | |
| GB0024704D0 (en) | Treatment of hyperproliferative skin disorders | |
| GB0219811D0 (en) | Treatment of excreta |